"
Team:Paris Bettencourt/Human Practice/Interview
From 2012.igem.org
(→Professor MAMZER-BRUNEEL) |
(→Professor MAMZER-BRUNEEL) |
||
| Line 9: | Line 9: | ||
==Professor MAMZER-BRUNEEL== | ==Professor MAMZER-BRUNEEL== | ||
| + | |||
| + | ===Presentation=== | ||
Professor MAMZER-BRUNEEL has a double PhD in Medicine and Ethiccs. She is currently a doctor at Necker Hospital in the kidney transplantation department. Furthemore, she is president of the "Advisory Council for the Protection of People Subject to Biomedical Research" and member of the "Laboratory of Ethics of Paris Decartes University". | Professor MAMZER-BRUNEEL has a double PhD in Medicine and Ethiccs. She is currently a doctor at Necker Hospital in the kidney transplantation department. Furthemore, she is president of the "Advisory Council for the Protection of People Subject to Biomedical Research" and member of the "Laboratory of Ethics of Paris Decartes University". | ||
| - | We are interviewing her as member of the laboratory of ethics of Paris Descartes as the "Advisory Council for the Protection of People Subject to Biomedical Research" does not deal with such issues | + | === Take home message === |
| + | We are interviewing her as a member of the laboratory of ethics of Paris Descartes as the "Advisory Council for the Protection of People Subject to Biomedical Research" does not deal with such issues: the harm to human beings would be indirect here(via a contaminated bacteria for example) and not direct. | ||
| + | |||
| + | Professor MAMZER-BRUNEEL thinks that there is no proper ethics commity that deals with such issues (indirect harms that genetically modifed organisms could cause to human populations) and thinks that this is a shame. She defined a proper ethics comity as follows: a comity who possesses representatives of the social society and not just of scientists. | ||
| - | She explained that for an ethics discussion to take place | + | She explained that for an ethics discussion to take place some elements need to be identified: |
| + | *What is the interest for the collectivity? | ||
| + | *What collectivity are we talking about? A certain group of people? All human beings? Animals? | ||
| + | *What is the exact field of application? | ||
| + | *What are the alternatives? | ||
| + | *What are the risks? (risk not limiting itself to toxicity). [To be evaluated by exeperts] | ||
| + | *How secure is the system? [To be evaluated by experts] | ||
| + | Then a balance benefits/risks can be established. | ||
==Professor AGUITON== | ==Professor AGUITON== | ||
Revision as of 21:46, 24 September 2012
- Main
- Team
- Project
- Achievements
- Human Practice
- Safety
- Notebook
- Attributions
Overview
Delay system
Semantic containment
Restriction enzyme system
MAGE
Suicide system
Encapsulation
Synthetic import domain
Safety Questions
Safety Assessment
Contents |
Aims
To talk with experts in different domain in order to orient our human practice.
Professor MAMZER-BRUNEEL
Presentation
Professor MAMZER-BRUNEEL has a double PhD in Medicine and Ethiccs. She is currently a doctor at Necker Hospital in the kidney transplantation department. Furthemore, she is president of the "Advisory Council for the Protection of People Subject to Biomedical Research" and member of the "Laboratory of Ethics of Paris Decartes University".
Take home message
We are interviewing her as a member of the laboratory of ethics of Paris Descartes as the "Advisory Council for the Protection of People Subject to Biomedical Research" does not deal with such issues: the harm to human beings would be indirect here(via a contaminated bacteria for example) and not direct.
Professor MAMZER-BRUNEEL thinks that there is no proper ethics commity that deals with such issues (indirect harms that genetically modifed organisms could cause to human populations) and thinks that this is a shame. She defined a proper ethics comity as follows: a comity who possesses representatives of the social society and not just of scientists.
She explained that for an ethics discussion to take place some elements need to be identified:
- What is the interest for the collectivity?
- What collectivity are we talking about? A certain group of people? All human beings? Animals?
- What is the exact field of application?
- What are the alternatives?
- What are the risks? (risk not limiting itself to toxicity). [To be evaluated by exeperts]
- How secure is the system? [To be evaluated by experts]
Then a balance benefits/risks can be established.
Professor AGUITON
Professor GOUYON
Professor MORANGE
Professor Ricroch
